You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.


Vertex, Idenix climb on rival’s stumble

David L Ryan/Globe Staff Photo/File

Vertex Pharmaceuticals’ new headquarters rises along Fan Pier.

Continue reading below

Locals Vertex Pharmaceuticals and Idenix Pharmaceuticals climbed after rival Gilead Sciences Inc. plunged after some patients on an experimental hepatitis C medicine relapsed after they stopped therapy. Gilead jumped into the race to develop a hepatitis C drug when it acquired Pharmasset Inc. for $10.8 billion. Gilead shares fell nearly 15 percent to $46.82. Vertex joined Merck & Co. last year in gaining approval for the first new hepatitis C drugs in almost a decade. Idenix also has developed medicines for the disease.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of